$2.11 EPS Expected for Waters Co. (NYSE:WAT) This Quarter

Wall Street brokerages forecast that Waters Co. (NYSE:WAT) will post earnings per share of $2.11 for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Waters’ earnings, with the highest EPS estimate coming in at $2.14 and the lowest estimate coming in at $2.09. Waters reported earnings per share of $1.95 in the same quarter last year, which would indicate a positive year over year growth rate of 8.2%. The company is expected to announce its next quarterly earnings report on Tuesday, July 23rd.

According to Zacks, analysts expect that Waters will report full-year earnings of $9.11 per share for the current year, with EPS estimates ranging from $9.07 to $9.17. For the next year, analysts expect that the business will post earnings of $10.26 per share, with EPS estimates ranging from $9.72 to $10.99. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Waters.

Waters (NYSE:WAT) last issued its earnings results on Tuesday, April 23rd. The medical instruments supplier reported $1.60 earnings per share for the quarter, missing the consensus estimate of $1.73 by ($0.13). Waters had a return on equity of 39.64% and a net margin of 24.59%. The firm had revenue of $513.90 million during the quarter, compared to analyst estimates of $545.82 million. During the same period in the previous year, the company earned $1.59 earnings per share. The business’s revenue for the quarter was down 3.2% on a year-over-year basis.

Several research analysts have weighed in on the company. Zacks Investment Research lowered Waters from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 12th. ValuEngine lowered Waters from a “buy” rating to a “hold” rating in a research report on Wednesday, April 24th. Robert W. Baird dropped their target price on Waters from $211.00 to $209.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 24th. Wolfe Research assumed coverage on Waters in a research report on Thursday, May 30th. They issued an “underperform” rating on the stock. Finally, Barclays dropped their target price on Waters from $218.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 24th. Four research analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $208.71.

WAT stock traded down $3.53 during mid-day trading on Wednesday, hitting $204.36. The stock had a trading volume of 870,149 shares, compared to its average volume of 623,612. The company has a debt-to-equity ratio of 1.15, a current ratio of 3.44 and a quick ratio of 2.89. Waters has a 1-year low of $167.93 and a 1-year high of $255.21. The firm has a market cap of $14.50 billion, a P/E ratio of 24.61, a PEG ratio of 2.20 and a beta of 1.08.

Several hedge funds and other institutional investors have recently modified their holdings of WAT. Athena Capital Advisors LLC acquired a new stake in Waters in the 4th quarter valued at approximately $28,000. Lindbrook Capital LLC acquired a new stake in Waters in the 4th quarter valued at approximately $41,000. Massey Quick Simon & CO. LLC acquired a new stake in Waters in the 1st quarter valued at approximately $43,000. Van ECK Associates Corp grew its holdings in Waters by 33.8% in the 4th quarter. Van ECK Associates Corp now owns 297 shares of the medical instruments supplier’s stock valued at $56,000 after buying an additional 75 shares during the last quarter. Finally, Enlightenment Research LLC acquired a new stake in Waters in the 4th quarter valued at approximately $57,000. 92.63% of the stock is currently owned by institutional investors and hedge funds.

Waters Company Profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Read More: Trading Penny Stocks

Get a free copy of the Zacks research report on Waters (WAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.